Navigation Links
One small step means giant leap for spinal cord research

A new device developed at the University of Toronto that stimulates the muscles of patients with spinal cord injuries helps to increase walking function in those whose condition is not expected to improve.

U of T researchers have found that functional electrical stimulation (FES), a process that sends controlled bursts of electricity through the skin and into muscles, can help patients improve their step frequency, stride length and overall walking speed.

"This is a group of patients in which recovery is not expected," says Professor Milos Popovic of the Institute of Biomaterials and Biomedical Engineering and the study's senior researcher. "We got them on a treadmill and worked with them and 18 weeks later we saw quite a considerable improvement."

Five patients, whose spinal cord injuries had taken place from two to 24 years prior to the study, completed two to five sessions per week of FES therapy. After practising with physiotherapists, the patients learned how to trigger their leg muscles as they walked. Over the course of 12 to 18 weeks, the patients gradually improved -- one woman was even able to stop using a full-length leg brace while walking.

While the patients' walking skills had decreased 10 weeks after treatment finished, the team found that overall walking skills were still considerably better than before the therapy. "It's truly rewarding when the patients are happy and they write you a little card saying, Without you, I could not walk," Popovic says. "In the next couple of years, I believe someone is going to develop a functional electrical stimulator that is suitable for this type of therapy and get it on the market," he says.

Popovic and colleagues are now conducting a similar study on a larger scale.


'"/>

Source:University of Toronto


Page: 1

Related biology news :

1. Stopping smallpox in its tracks: A new anti-viral approach
2. New World founders small in number
3. Secret of smallpoxs success may lead to bioterror cure
4. Circulating stem cells play small role in lung repair
5. No small feat: First ever gene therapy success for muscular dystrophy achieved
6. LIAI scientists make major finding on potential smallpox treatment
7. Researchers develop new testing methods for potential monkeypox or smallpox outbreak
8. Solexa and collaborating scientists illuminate the small RNA component of the transcriptome
9. Delaware scientists make significant advance in study of small RNAs
10. Scientists learn to predict protein-stabilizing ability of small molecules
11. New study of the worlds smallest elephant
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 24, 2017  VWR Corporation (NASDAQ: VWR), the leading global ... production customers, today reported its financial results for the fourth ... Highlights: 4Q16 record quarterly net sales ... an organic basis. 4Q16 EMEA-APAC ... basis, while the Americas net sales increased 2.5%, or down ...
(Date:2/23/2017)... 23, 2017 ... per share data, unaudited)Three Months Ended December 31,Twelve Months ... $         ...   89026%Aldurazyme Net Product Revenue ... Net Product Revenue  756025%297303(2)%Vimizim Net ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017  MIODx ... license for two key immunotherapy technologies from the ... technology provides a method to monitor a patient ... as PD-L1 and CTLA-4.  The second license extends ... a patient is likely to have an immune-related ...
(Date:2/23/2017)... 23, 2017  Imanis Life Sciences announced today ... oncolytic vaccinia viruses for virotherapy research. These viruses ... Genelux,s proprietary, vaccinia virus-based technology platform for research ... into a partnership with Genelux to offer researchers, ... for use in research," said Dr. Kah ...
Breaking Biology Technology: